Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas

التفاصيل البيبلوغرافية
العنوان: Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas
المؤلفون: Hirokazu Ogino, Jennie W. Taylor, Takahide Nejo, David Gibson, Payal B. Watchmaker, Kaori Okada, Atsuro Saijo, Meghan R. Tedesco, Anny Shai, Cynthia M. Wong, Jane E. Rabbitt, Michael R. Olin, Christopher L. Moertel, Yasuhiko Nishioka, Andres M. Salazar, Annette M. Molinaro, Joanna J. Phillips, Nicholas A. Butowski, Jennifer L. Clarke, Nancy Ann Oberheim Bush, Shawn L. Hervey-Jumper, Philip Theodosopoulos, Susan M. Chang, Mitchel S. Berger, Hideho Okada
المصدر: The Journal of clinical investigation, vol 132, iss 3
The Journal of Clinical Investigation
بيانات النشر: eScholarship, University of California, 2022.
سنة النشر: 2022
مصطلحات موضوعية: Adult, Male, and promotion of well-being, Clinical Trials and Supportive Activities, Immunology, T cells, Cancer immunotherapy, CD8-Positive T-Lymphocytes, Brain cancer, Cancer Vaccines, Medical and Health Sciences, Vaccine Related, Rare Diseases, Clinical Research, Tumor Microenvironment, Humans, Polylysine, Aged, Cancer, Vaccines, Prevention, Vaccination, Neurosciences, Evaluation of treatments and therapeutic interventions, General Medicine, Glioma, Middle Aged, Prevention of disease and conditions, Neoadjuvant Therapy, Brain Disorders, Poly I-C, Orphan Drug, Good Health and Well Being, Oncology, 3.4 Vaccines, Carboxymethylcellulose Sodium, 6.1 Pharmaceuticals, Female, Immunization, Clinical Medicine, Infection, Biotechnology
الوصف: BACKGROUND Long-term prognosis of WHO grade II low-grade gliomas (LGGs) is poor, with a high risk of recurrence and malignant transformation into high-grade gliomas. Given the relatively intact immune system of patients with LGGs and the slow tumor growth rate, vaccines are an attractive treatment strategy. METHODS We conducted a pilot study to evaluate the safety and immunological effects of vaccination with GBM6-AD, lysate of an allogeneic glioblastoma stem cell line, with poly-ICLC in patients with LGGs. Patients were randomized to receive the vaccines before surgery (arm 1) or not (arm 2) and all patients received adjuvant vaccines. Coprimary outcomes were to evaluate safety and immune response in the tumor. RESULTS A total of 17 eligible patients were enrolled — 9 in arm 1 and 8 in arm 2. This regimen was well tolerated with no regimen-limiting toxicity. Neoadjuvant vaccination induced upregulation of type-1 cytokines and chemokines and increased activated CD8+ T cells in peripheral blood. Single-cell RNA/T cell receptor sequencing detected CD8+ T cell clones that expanded with effector phenotype and migrated into the tumor microenvironment (TME) in response to neoadjuvant vaccination. Mass cytometric analyses detected increased tissue resident–like CD8+ T cells with effector memory phenotype in the TME after the neoadjuvant vaccination. CONCLUSION The regimen induced effector CD8+ T cell response in peripheral blood and enabled vaccine-reactive CD8+ T cells to migrate into the TME. Further refinements of the regimen may have to be integrated into future strategies. TRIAL REGISTRATION ClinicalTrials.gov NCT02549833. FUNDING NIH (1R35NS105068, 1R21CA233856), Dabbiere Foundation, Parker Institute for Cancer Immunotherapy, and Daiichi Sankyo Foundation of Life Science.
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7be027edfe85ce3bf383e785759b0027Test
https://escholarship.org/uc/item/00d0f4fmTest
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....7be027edfe85ce3bf383e785759b0027
قاعدة البيانات: OpenAIRE